Advancing discovery of risk-altering variants for complex diseases by functionally informed fine-mapping.

Area of Science:

• Genetics
• Neuroscience
• Genomic Medicine

Background:

• Genome-wide association studies (GWAS) identify genomic regions associated with diseases but struggle to pinpoint specific causal variants.
• Prioritizing causal variants within these risk loci is essential for understanding disease mechanisms and developing targeted therapies.
• Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease where identifying causative genetic factors remains a significant challenge.

Purpose of the Study:

• To present a novel fine-mapping approach, RefMap, designed to prioritize causal variants for complex diseases.
• To apply RefMap to identify potential causal variants associated with amyotrophic lateral sclerosis (ALS).

Main Methods:

• RefMap integrates functional genomics data with summary statistics from genome-wide association studies (GWAS).
• The method leverages information on gene expression, chromatin accessibility, and other functional elements to refine variant prioritization.
• Statistical models are employed to weigh evidence from GWAS and functional data.

Main Results:

• The RefMap approach successfully prioritized a set of candidate causal variants for amyotrophic lateral sclerosis (ALS).
• Integration of functional genomics data significantly improved the resolution of variant mapping compared to GWAS alone.
• The study identified specific variants potentially driving ALS risk at known GWAS loci.

Conclusions:

• RefMap offers a powerful strategy for fine-mapping genetic risk loci and prioritizing causal variants in complex diseases.
• This approach can accelerate the discovery of disease mechanisms and therapeutic targets for conditions like ALS.
• Integrating functional genomics with GWAS is crucial for advancing precision medicine.